Search clinical trials for: PD-1 inhibitor Gemcitabine Cisplatin

Total 8326 results

Gyeongsang National University Hospital
Samsung Medical Center; Dong-A University; Chung-Ang University

Terminated

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

Korea, Republic of
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Neoadjuvant Therapy | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Kansai Hepatobiliary Oncology Group

Completed

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Sun Yat-sen University

Recruiting

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China
Kansai Hepatobiliary Oncology Group

Unknown

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Japan
European Organisation for Research and Treatment...

Completed

Pembrolizumab in Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer | Gallbladder Cancer

United Kingdom, Spain, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Not yet recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Chinese PLA General Hospital

Unknown

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Biliary Tract Cancer

China
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
Zhejiang University

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma by AJCC V8 Stage

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Sun Yat-sen University
Bristol-Myers Squibb

Active, not recruiting

Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma (PLATINUM)

Nasopharyngeal Carcinoma

China
Wei Jiang
Wuzhou Red Cross Hospital; Guangxi Nanxishan Hospital; Laibin People's Hospital; Lingshan people's Hospital

Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Kansai Hepatobiliary Oncology Group

Completed

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Hannover Medical School

Completed

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PiCCA)

Cholangiocarcinomas

Germany
Ruijin Hospital

Not yet recruiting

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

China
Jiangxi Provincial Cancer Hospital

Recruiting

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Nasopharyngeal Carcinoma

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Nasopharyngeal Carcinoma | De-escalation Therapy

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Head and Neck Squamous Cell Carcinoma

China
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

United States
Sun Yat-sen University

Recruiting

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Classical Hodgkin Lymphoma | Refractory or Relapsed Classical Hodgkin Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Asan Medical Center

Completed

Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma

Metastatic Biliary Cancer

Korea, Republic of
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...

Recruiting

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Objective Response Rate

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
Sun Yat-sen University

Unknown

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China

Search clinical trials for: PD-1 inhibitor Gemcitabine Cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations